Duchenne News Tags: Entrada Therapeutics

November 27, 2023
Entrada announces the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.
November 7, 2023
Entrada reports third quarter 2023 financial results and more business updates.
September 21, 2023
Entrada announces the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44...
August 7, 2023
Entrada announces authorization for its CTIMP for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44
January 10, 2023
Entrada announces the selection of a second clinical candidate within its Duchenne franchise, ENTR-601-45
December 21, 2022
Entrada announces clinical hold notice from U.S. FDA regarding IND for ENTR-601-44

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open